Impressive Clinical Results Show Medtronic, Inc. ENDEAVOR(TM) Drug-Eluting Coronary Stent Provides Significant Long-Term Safety And Efficacy Benefits

PARIS--(BUSINESS WIRE)--May 16, 2006--Prof. Ian Meredith, Principal Investigator of the ENDEAVOR I clinical trial and Professor of Medicine, Monash Medical Centre, Melbourne, Australia, today presented impressive long-term clinical results from the Medtronic (NYSE:MDT - News) ENDEAVOR I and ENDEAVOR II trials at the Paris Course on Revascularization (EuroPCR). Data from the two studies shows that the Endeavor(TM) drug-eluting coronary stent is continuing to provide significant and sustained efficacy and safety performance over time, with low rates of repeat procedures and no observations of late stent thrombosis.

Back to news